Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4): A post hoc analysis of the SUNSHINE and SUNRISE trials.

Autor: Zouboulis CC; European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany.; Departments of Dermatology, Venereology, Allergology and Immunology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, Germany., Kyrgidis A; European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany.; Department of Maxillofacial Surgery, Papanikolaou General Hospital of Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece., Alavi A; European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany.; Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA., Jemec GBE; European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany.; Department of Dermatology, Zeeland University Hospital, Roskilde, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Martorell A; European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany.; Department of Dermatology, Hospital de Manises, Valencia, Spain., Marzano AV; European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany.; Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.; Department of Pathophysiology and Transplantation, Università Degli Studi di Milano, Milan, Italy., van der Zee HH; European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany.; Department of Dermatology, Erasmus Medical Center, Rotterdam, The Netherlands., Wozniak MB; Novartis Ireland Limited, Dublin, Ireland., Martinez AL; Novartis Pharma AG, Basel, Switzerland., Kasparek T; Novartis Pharma AG, Basel, Switzerland., Bachhuber T; Novartis Pharma AG, Basel, Switzerland., Ortmann CE; Novartis Pharma AG, Basel, Switzerland., Lobach I; Novartis Ireland Limited, Dublin, Ireland., Thomas N; Novartis Pharma AG, Basel, Switzerland., Ravichandran S; Novartis Pharmaceuticals, East Hanover, New Jersey, USA., Tzellos T; European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany.; Department of Dermatology, Nordland Hospital Trust, Bodø, Norway.

Publikováno v: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2024 Oct 19. Date of Electronic Publication: 2024 Oct 19.

Secukinumab versus guselkumab in the complete resolution of ustekinumab-resistant psoriatic plaques: The ARROW study.

Autor: Krueger J; Laboratory of Investigative Dermatology, The Rockefeller University, New York, New York, USA., Langley RG; Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada., Nigen S; Sima Recherche, Université de Montréal, Montreal, Quebec, Canada., Kasparek T; Novartis Pharma AG, Basel, Switzerland., Di Comite G; Novartis Pharma K.K., Tokyo, Japan., Ortmann CE; Novartis Pharma AG, Basel, Switzerland., Garcet S; Laboratory of Investigative Dermatology, The Rockefeller University, New York, New York, USA., Kolbinger F; Novartis Institutes for BioMedical Research, Basel, Switzerland., Reich K; Translational Research in Inflammatory Skin Disease, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Publikováno v: Experimental dermatology [Exp Dermatol] 2023 Oct; Vol. 32 (10), pp. 1834-1847. Date of Electronic Publication: 2023 Jun 05.

Lower Limbs are the Most Difficult-to-Treat Body Region of Patients with Psoriasis: Pooled Analysis of CLEAR and CLARITY Studies of Secukinumab Versus Ustekinumab by Body Region.

Autor: Alpalhão M; Dermatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal. migueldbalpalhao@campus.ul.pt.; Dermatology University Clinic, Faculty of Medicine, University of Lisbon, Lisbon, Portugal. migueldbalpalhao@campus.ul.pt.; Dermatology Research Unit, iMM Lobo Antunes, University of Lisbon, Lisbon, Portugal. migueldbalpalhao@campus.ul.pt., Duarte J; Medical Department-IHD, Novartis Pharma, Lisbon, Portugal., Diogo R; Medical Department-IHD, Novartis Pharma, Lisbon, Portugal., Vandemeulebroecke M; Novartis Pharma AG, Basel, Switzerland., Ortmann CE; Novartis Pharma AG, Basel, Switzerland., Kasparek T; Novartis Pharma AG, Basel, Switzerland., Filipe P; Dermatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.; Dermatology University Clinic, Faculty of Medicine, University of Lisbon, Lisbon, Portugal.; Dermatology Research Unit, iMM Lobo Antunes, University of Lisbon, Lisbon, Portugal.

Publikováno v: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy [BioDrugs] 2022 Nov; Vol. 36 (6), pp. 781-789. Date of Electronic Publication: 2022 Nov 05.

Secukinumab effects on disease burden, patient needs and benefits, and treatment satisfaction in patients with plaque psoriasis across European regions: patient perspective data from the PROSE study.

Autor: da Silva N; Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Sommer R; Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Ortmann CE; Novartis Pharma AG, Basel, Switzerland., Jagiello P; Novartis Pharma AG, Basel, Switzerland., Bachhuber T; Novartis Pharma AG, Basel, Switzerland., Augustin M; Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Publikováno v: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2021 Nov; Vol. 35 (11), pp. 2241-2249. Date of Electronic Publication: 2021 Jul 31.

Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study.

Autor: Lacroix A; Centre hospitalier de l'Université de Montréal, 3840 Saint-Urbain, Montreal, H2W1T8, Canada. andre.lacroix@umontreal.ca., Bronstein MD; University of São Paulo Medical School, São Paulo, Brazil., Schopohl J; Medizinische Klinik und Poliklinik IV, Ludwig-Maximilians-Universität München, Munich, Germany., Delibasi T; Hacettepe University, Ankara, Turkey., Salvatori R; Division of Endocrinology, Diabetes and Metabolism, and Pituitary Center, Johns Hopkins University, Baltimore, MD, USA., Li Y; Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China., Barkan A; University of Michigan, Ann Arbor, MI, USA., Suzaki N; Nagoya Medical Center, National Hospital Organization, Nagoya, Japan., Tauchmanova L; Novartis Pharma AG, Basel, Switzerland., Ortmann CE; Novartis Pharma AG, Basel, Switzerland., Ravichandran S; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Petersenn S; ENDOC Center for Endocrine Tumors, Hamburg, Germany., Pivonello R; Università Federico II di Napoli, Naples, Italy.

Publikováno v: Journal of endocrinological investigation [J Endocrinol Invest] 2020 Nov; Vol. 43 (11), pp. 1613-1622. Date of Electronic Publication: 2020 May 08.